Lupus & antiphospholipid syndrome
Belimumab therapy for refractory immune thrombocytopenia in systemic lupus erythematosus patients with anti-phospholipid antibodies
Authors' conclusion
In this study, belimumab reduced the anti-phospholipid antibodies while increasing the platelet count in SLE patients with anti-phospholipid antibody-associated immune thrombocytopenia.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients (1997 ACR criteria) with refractory aPL-associated immune thrombocytopenia (platelets <30 × 109/L), no bleeding symptoms, lack of satisfactory response to traditional treatment and high-titre aPL
- Participants
- 4 patients
- Outcome
- Platelet count
Methodological detailsone-arm
- One-arm
Main finding
As reported in the abstract
Mean platelet count at baseline
21.8 × 109 cells/L
Platelet count range at baseline
16 and 29 × 109/L
Platelet count at 1 month
123.3 × 109/L
Platelet count at the end of 6 months
172.5 × 109/L
Observational data: associations, not effects.
Safety
- No bleeding complications occurred during the entire follow-up period
Original publication
Belimumab therapy for refractory immune thrombocytopenia in systemic lupus erythematosus patients with anti-phospholipid antibodies. Scand J Rheumatol. Published 31 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →